Highlights
- 1Annals of internal medicine · 2023
- 2Trends in neurosciences · 2022
- 3
Publications
44 publications
Funding
15 grantsView NIH portfolio on RePORTER ↗
Active
8 grants- KPP30AI191337-01A1Columbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
- Co-IR37AI189285-02Characterization of Allogeneic T cells mediating HIV cureNational Institute of Allergy and Infectious Diseases · 2025–2030 · via Oregon Health & Science University
- MPIUM1AI068636-16S2Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG)National Institute of Allergy and Infectious Diseases · 2020–2027 · via University of California, Los Angeles· 2 renewals
- Co-IUM1AI069419-15Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitNational Institute of Allergy and Infectious Diseases · 2020–2027
- Co-IUM1AI164565-06REACH: Research Enterprise to Advance a Cure for HIVNational Institute of Allergy and Infectious Diseases · 2021–2027· 2 renewals
- KPUL1TR002384-06Clinical and Translational Science Center - UL1National Center for Advancing Translational Sciences · 2022–2027
- Co-IR01MH130197-02Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistenceNational Institute of Mental Health · 2023–2027 · via Henry M. Jackson Foundation for the Advancement of Military Medicine
- Co-IR01AG063846-01A1Harnessing Single Cell Epigenome-wide profiling of Myeloid cells to Compare and Contrast Alzheimer's from HIV-Associated Cognitive DysfunctionNational Institute on Aging · 2020–2026
Completed grants (7)
- Co-IR56AG078970-02The Role of Transposable Elements in Healthy Aging and in Alzheimer's DiseaseNational Institute on Aging · 2022–2025 · via The Feinstein Institute for Medical Research· 2 renewals
- PIR21AG071433-02Leveraging Directly Reprogrammed Human Neurons to Investigate the Molecular Impact of Age and Distinct Antiretroviral Therapies in Individuals Living with HIV-1National Institute on Aging · 2021–2024
- PITCF 204850-01Investigating the Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) for Measures of Cardiovascular Disease Risk and Neurocognitive Impairment in People Living with HIV-1The Campbell Foundation · 2021–2024
- Sub-PIR01AI145570-05Single-Cell Analysis of HIV-1 Production and TransmissionNational Institute of Allergy and Infectious Diseases · 2021–2024 · via Columbia University
- PIR21NS126094-01A Precision Medicine Approach to Investigating the Molecular Impact of Age and Neurocognitive Impairment in People Living with HIV (PLWH)National Institute of Neurological Disorders and Stroke · 2021–2024
- PIRWJF 78496Investigating the Impact of Race on Gene-Expression Profiles in HIV- Associated Neurocognitive DisordersRobert Wood Johnson Foundation · 2021–2023
Clinical research
9 studies
Active
5 studies- PINCT06705478An Open-Label, Randomized Controlled Trial of Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIVPHASE2 · National Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2026)Major Depressive Disorder; Mild Neurocognitive Disorder; HIV
- PIInvestigating Immune Responses Mediating HIV Cure Following Allogeneic Stem Cell TransplantationWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PIThe WCM Advancing HIV Health through Epigenetic studies in Aging and Alzheimer's Disease (AHEAD) StudyWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2023)
- PIEffect of IL-15 super-agonist administration on Neurologic safety and Antiviral CD8+ T cells responses in the CSF: A Substudy to NIH ACTG A5386: N-803 With Or Without Bnabs For HIV-1 Control In Participants Living With HIV-1 On Suppressive ARTWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2023)
- PIInvestigating Techniques for the Characterization, Reactivation and Elimination of the latent HIV-1 ReservoirWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2021)
Completed & closed trials (4)
- PIDeveloping Directly Reprogrammed Human Neurons to Investigate the Molecular Basis of Neurodegeneration in HIV and AgingThe Rockefeller University · CLOSED TO ACCRUAL (as of 2025)
- PINCT04518410Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)PHASE2; PHASE3 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2023)Coronavirus; Covid19
- PISARS-CoV-2 Immune Responses after COVID-19 Therapy and _x000D_ Subsequent VaccineNational Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2022)
- PIEstablishment and Characterization of a Severe Acute Respiratory Syndrome Coronavirus 2 _x000D_ (SARS-CoV-2) Cohort in Humans to Understand Disease PathogenesisWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2021)
News mentions
4 mentionsView all WCM news ↗
- New Clues to Understanding HIV-related Cognitive ImpairmentJanuary 14, 2026
Using participant skin cells reprogrammed into neurons, Weill Cornell Medicine researchers have identified genetic signatures associated with HIV infection that may contribute to the cognitive impairment that often occurs in people living with the disease, even when the virus is controlled.
- Search Continues for a Treatment that Reduces Long COVID SymptomsOctober 17, 2024
Researchers at Weill Cornell Medicine found that a combination of therapeutic monoclonal antibodies called amubarvimab and romlusevimab did not reduce the occurrence of long COVID symptoms.
- Antibody Combination Provided Strong Protection Against Severe COVID-19 in Large International TrialApril 19, 2023
A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial conducted in the first half of 2021 and co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.
- Mission Possible: Weill Cornell Medicine Launches an Unprecedented Research Effort in the Battle Against COVID-19March 2, 2021
Soon after the first case of COVID-19 was reported in New York City last March, a group of about 10 physician-scientists at Weill Cornell Medicine met to discuss a pressing issue: there were no known treatments for severe cases of the disease.
Mentoring
1 menteeAll publications with mentees →
- POPhilipp OstermannPostdoc mentee · 2022–2023